Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.

Wang CX, Liu B, Wang YF, Zhang RS, Yu B, Lu ZF, Shi QL, Zhou XJ.

Int J Clin Exp Pathol. 2014 Feb 15;7(3):1266-74. eCollection 2014.

2.

[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.

PMID:
23157740
3.

KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.

Krasinskas AM, Chiosea SI, Pal T, Dacic S.

Mod Pathol. 2014 Feb;27(2):262-70. doi: 10.1038/modpathol.2013.146. Epub 2013 Jul 26.

4.

Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H.

J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8.

5.

CDX-2 Expression in Primary Lung Adenocarcinoma.

Cowan ML, Li QK, Illei PB.

Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):16-9. doi: 10.1097/PAI.0000000000000250.

PMID:
26469326
6.

Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.

Sousa V, Rodrigues C, Silva M, Alarcão AM, Carvalho L.

Rev Port Pneumol (2006). 2015 May-Jun;21(3):113-25. doi: 10.1016/j.rppnen.2014.09.009. Epub 2015 Mar 11.

PMID:
25926253
7.

Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.

Mackinnon AC Jr, Luevano A, de Araujo LC, Rao N, Le M, Suster S.

Mod Pathol. 2014 Aug;27(8):1063-72. doi: 10.1038/modpathol.2013.227. Epub 2014 Jan 3.

8.

High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.

Morita S, Yoshida A, Goto A, Ota S, Tsuta K, Yokozawa K, Asamura H, Nakajima J, Takai D, Mori M, Oka T, Tamaru J, Itoyama S, Furuta K, Fukayama M, Tsuda H.

Am J Surg Pathol. 2013 Jun;37(6):924-32. doi: 10.1097/PAS.0b013e31827e1e83.

PMID:
23629442
9.

Impact of GLUT1 and Ki-67 expression on early‑stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification.

Maki Y, Soh J, Ichimura K, Shien K, Furukawa M, Muraoka T, Tanaka N, Ueno T, Yamamoto H, Asano H, Tsukuda K, Toyooka S, Miyoshi S.

Oncol Rep. 2013 Jan;29(1):133-40. doi: 10.3892/or.2012.2087. Epub 2012 Oct 17.

PMID:
23076555
10.

EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.

Yang Y, Yang Y, Zhou X, Song X, Liu M, He W, Wang H, Wu C, Fei K, Jiang G.

Lung Cancer. 2015 Mar;87(3):272-7. doi: 10.1016/j.lungcan.2014.12.016. Epub 2015 Jan 5.

PMID:
25582278
11.

Pulmonary enteric adenocarcinoma indistinguishable morphologically and immunohistologically from metastatic colorectal carcinoma.

László T, Lacza A, Tóth D, Molnár TF, Kálmán E.

Histopathology. 2014 Aug;65(2):283-7. doi: 10.1111/his.12403. Epub 2014 Apr 23. No abstract available.

PMID:
24571601
12.
13.

HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.

Sugano M, Nagasaka T, Sasaki E, Murakami Y, Hosoda W, Hida T, Mitsudomi T, Yatabe Y.

Am J Surg Pathol. 2013 Feb;37(2):211-8. doi: 10.1097/PAS.0b013e31826be303.

PMID:
23108025
14.

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.

Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL.

Mod Pathol. 2013 Oct;26(10):1307-19. doi: 10.1038/modpathol.2013.74. Epub 2013 Apr 26.

15.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

16.

Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.

McCluggage WG, Shah R, Connolly LE, McBride HA.

Int J Gynecol Pathol. 2008 Jan;27(1):92-100.

PMID:
18156982
17.

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.

Cancer Cytopathol. 2013 Sep;121(9):500-7. doi: 10.1002/cncy.21288. Epub 2013 Mar 12.

18.

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.

de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.

Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.

PMID:
25833149
19.

Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.

Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y.

Lung Cancer. 2010 Oct;70(1):94-102. doi: 10.1016/j.lungcan.2010.01.001. Epub 2010 Feb 1.

PMID:
20117855
20.

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Aug;38(8):1118-27. doi: 10.1097/PAS.0000000000000246.

Supplemental Content

Support Center